On this page
Hydrocortisone Acetate Pramoxine Hcl
Overview
Active ingredients
Source: NDC DirectoryForms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Corticosteroid Hormone Receptor Agonists [MoA] | MoA | All 215 members |
| Corticosteroid [EPC] | EPC | All 215 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 085368-001 | PRAMOSONE | CREAM | HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE | Prescription | — |
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 23 | Manufacturing (CMC) | Approved | December 6, 2001 | — |
| Supplement | 22 | Manufacturing (CMC) | Approved | September 21, 2001 | — |
| Supplement | 21 | Manufacturing (CMC) | Approved | September 21, 2001 | — |
| Supplement | 20 | Manufacturing (CMC) | Approved | February 5, 2001 | — |
| Supplement | 19 | Manufacturing (CMC) | Approved | September 21, 2000 | — |
| Supplement | 18 | Manufacturing (CMC) | Approved | August 11, 2000 | — |
| Supplement | 17 | Manufacturing (CMC) | Approved | March 1, 1999 | — |
| Supplement | 16 | Manufacturing (CMC) | Approved | August 20, 1992 | — |
| Supplement | 15 | Labeling | Approved | June 3, 1992 | — |
| Supplement | 14 | Manufacturing (CMC) | Approved | June 3, 1992 | — |
| Supplement | 13 | Manufacturing (CMC) | Approved | June 3, 1992 | — |
| Supplement | 11 | Labeling | Approved | June 3, 1992 | — |
| Supplement | 12 | Manufacturing (CMC) | Approved | April 27, 1992 | — |
| Supplement | 9 | Manufacturing (CMC) | Approved | April 27, 1992 | — |
| Supplement | 8 | Labeling | Approved | April 27, 1992 | — |
| Supplement | 10 | Manufacturing (CMC) | Approved | November 7, 1988 | — |
| Supplement | 7 | Manufacturing (CMC) | Approved | December 21, 1984 | — |
| Supplement | 6 | Manufacturing (CMC) | Approved | December 21, 1984 | — |
| Original application | 1 | Approved | January 7, 1977 | — |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20251024). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Topical corticosteroids are generally applied to the affected area as a thin film three to four times daily depending on the severity of the condition. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: Burning Hypertrichosis Maceration of the skin Itching Acneiform eruptions Secondary infection Irritation Hypopigmentation Skin atrophy Dryness Perioral dermatitis Striae Folliculitis Allergic contact dermatitis Miliaria To report SUSPECTED ADVERSE REACTIONS, contact Saptalis Pharmaceuticals, LLC at 1-833-727-8254 or FDA at 1800-FDA-1088 or www.fda.gov/medwatch.
Description
openFDA Drug LabelingDESCRIPTION Hydrocortisone Acetate 2.5% and Pramoxine HCl 1% Cream is a topical preparation containing hydrocortisone acetate 2.5% w/w and pramoxine hydrochloride 1% w/w in a hydrophilic cream base containing stearic acid, cetyl alcohol, Aquaphor®, isopropyl palmitate, polyoxyl 40 stearate, propylene glycol, potassium sorbate, sorbic acid, triethanolamine lauryl sulfate, and purified water. Topical corticosteroids are anti-inflammatory and anti-pruritic agents. The structural formula, the chemical name, molecular formula and molecular weight for the active ingredients are presented below. hydrocortisone acetate Pregn-4-ene-3, 20-dione, 21-(acetyloxy)-11, 17-dihydroxy-, (11-beta)- C 23 H 32 O 6 ; mol. wt: 404.50 pramoxine hydrochloride 4-(3-(p-butoxyphenoxy)propyl)morpholine hydrochloride C 17 H 27 NO 3 .HCl; mol. wt: 329.87 Chemical Structure Chemical Structure
Overdosage
openFDA Drug LabelingOVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects. (See PRECAUTIONS . )
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Hydrocortisone Acetate 2.5% and Pramoxine HCl 1% Cream is available as follows: NDC: 71335-2934-1: 57 g in a TUBE Store at 25oC (77oF); excursions permitted to 15-30oC (59-86oF) [see USP Controlled Room Temperature]. Repackaged/Relabeled by: Bryant Ranch Prepack, Inc. Burbank, CA 91504
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: HYDROCORTISONE ACETATE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 63629-8669-1 | 63629-8669 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (63629-8669-1) / 28.35 g in 1 TUBE | April 13, 2010 |
| 63629-8670-1 | 63629-8670 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (63629-8670-1) / 28.35 g in 1 TUBE | July 20, 2021 |
| 63629-8671-1 | 63629-8671 | Bryant Ranch Prepack | 12 TUBE in 1 CARTON (63629-8671-1) / 4 g in 1 TUBE | July 20, 2021 |
| 63629-8672-1 | 63629-8672 | Bryant Ranch Prepack | 30 TUBE in 1 CARTON (63629-8672-1) / 4 g in 1 TUBE | July 20, 2021 |
| 63629-8673-1 | 63629-8673 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (63629-8673-1) / 28.4 g in 1 TUBE | July 20, 2021 |
| 63629-8674-1 | 63629-8674 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (63629-8674-1) / 57 g in 1 TUBE | March 29, 2011 |
| 71335-2932-1 | 71335-2932 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (71335-2932-1) / 28.35 g in 1 TUBE | October 28, 2025 |
| 71335-2934-1 | 71335-2934 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (71335-2934-1) / 57 g in 1 TUBE | October 24, 2025 |
| 71335-2939-1 | 71335-2939 | Bryant Ranch Prepack | 12 TUBE in 1 CARTON (71335-2939-1) / 4 g in 1 TUBE | October 28, 2025 |
| 71335-2942-1 | 71335-2942 | Bryant Ranch Prepack | 30 TUBE in 1 CARTON (71335-2942-1) / 4 g in 1 TUBE | October 28, 2025 |
| 72162-1394-2 | 72162-1394 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-1394-2) / 57 g in 1 TUBE | December 24, 2024 |
| 72162-1394-4 | 72162-1394 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-1394-4) / 28.4 g in 1 TUBE | December 24, 2024 |
| 72162-1399-3 | 72162-1399 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-1399-3) / 28.35 g in 1 TUBE | August 17, 2023 |
| 72162-1411-2 | 72162-1411 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-1411-2) / 28.35 g in 1 TUBE | December 24, 2024 |
| 72162-1411-3 | 72162-1411 | Bryant Ranch Prepack | 30 TUBE in 1 CARTON (72162-1411-3) / 4 g in 1 TUBE | December 24, 2024 |
| 72162-1411-4 | 72162-1411 | Bryant Ranch Prepack | 12 TUBE in 1 CARTON (72162-1411-4) / 4 g in 1 TUBE | December 24, 2024 |
| 45802-124-16 | 45802-124 | Padagis Israel Pharmaceuticals Ltd | 1 TUBE in 1 CARTON (45802-124-16) / 57 g in 1 TUBE | March 29, 2011 |
| 45802-124-64 | 45802-124 | Padagis Israel Pharmaceuticals Ltd | 1 TUBE in 1 CARTON (45802-124-64) / 28.4 g in 1 TUBE | March 29, 2017 |
| 45802-144-64 | 45802-144 | Padagis Israel Pharmaceuticals Ltd | 1 TUBE in 1 CARTON (45802-144-64) / 28.35 g in 1 TUBE | April 13, 2010 |
| 45802-472-53 | 45802-472 | Padagis Israel Pharmaceuticals Ltd | 12 TUBE in 1 CARTON (45802-472-53) / 4 g in 1 TUBE (45802-472-01) | May 3, 2010 |
| 45802-472-64 | 45802-472 | Padagis Israel Pharmaceuticals Ltd | 1 TUBE in 1 CARTON (45802-472-64) / 28.35 g in 1 TUBE | April 13, 2010 |
| 45802-472-65 | 45802-472 | Padagis Israel Pharmaceuticals Ltd | 30 TUBE in 1 CARTON (45802-472-65) / 4 g in 1 TUBE (45802-472-01) | May 3, 2010 |
| 52817-817-01 | 52817-817 | TRUPHARMA, LLC | 1 TUBE in 1 CARTON (52817-817-01) / 28.4 g in 1 TUBE | November 19, 2020 |
| 63629-8669 | 63629-8669 | Bryant Ranch Prepack | — | April 13, 2010 |
| 63629-8670 | 63629-8670 | Bryant Ranch Prepack | — | September 27, 1996 |
| 63629-8671 | 63629-8671 | Bryant Ranch Prepack | — | September 27, 1996 |
| 63629-8672 | 63629-8672 | Bryant Ranch Prepack | — | September 27, 1996 |
| 63629-8673 | 63629-8673 | Bryant Ranch Prepack | — | March 29, 2011 |
| 63629-8674 | 63629-8674 | Bryant Ranch Prepack | — | March 29, 2011 |
| 71335-2932 | 71335-2932 | Bryant Ranch Prepack | — | September 27, 1996 |
| 71335-2934 | 71335-2934 | Bryant Ranch Prepack | — | March 29, 2011 |
| 71335-2939 | 71335-2939 | Bryant Ranch Prepack | — | September 27, 1996 |
| 71335-2942 | 71335-2942 | Bryant Ranch Prepack | — | September 27, 1996 |
| 72162-1394 | 72162-1394 | Bryant Ranch Prepack | — | March 29, 2011 |
| 72162-1399 | 72162-1399 | Bryant Ranch Prepack | — | April 13, 2010 |
| 72162-1411 | 72162-1411 | Bryant Ranch Prepack | — | September 27, 1996 |
| 45802-124 | 45802-124 | Padagis Israel Pharmaceuticals Ltd | — | March 29, 2011 |
| 45802-144 | 45802-144 | Padagis Israel Pharmaceuticals Ltd | — | April 13, 2010 |
| 45802-472 | 45802-472 | Padagis Israel Pharmaceuticals Ltd | — | September 27, 1996 |
| 52817-817 | 52817-817 | TRUPHARMA, LLC | — | November 19, 2020 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 10 sections on this page.